The South American Trade Agreement (MERCOSUR) and the EU concluded decades-long negotiations and signed a deal to swap goods and services freely across the Atlantic.
Argentina, Brazil, Uruguay and Paraguay, the founding members of MERCOSUR, scored a win as many see them as the true winners of this trade pact. Propelled by a right-wing wave in the South American block and opportunistic strategies by Europe to defend itself from new USA protectionism. But how does this impact the pharmaceutical market and R&D spending?
The next free trade agreement in the pipeline includes Korea, another pharma power house.